Actively Recruiting
Observational Safety Study of Anifrolumab in Moderate to Severe Systemic Lupus Erythematosus Patients Assessing Malignancies and Serious Infections
Led by AstraZeneca · Updated on 2026-09-16
3506
Participants Needed
4
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting an observational study to assess the risk of malignancies and serious infections in people with moderate to severe systemic lupus erythematosus SLE. This study compares patients who receive the drug anifrolumab with those who receive standard care but do not start anifrolumab. The goal is to better understand safety outcomes related to these treatments in real-world settings. Participants prescribed anifrolumab according to local medical practice will be observed alongside a similar group receiving standard care. The study tracks incidents of malignancies and serious infections, including infections that result in hospitalization or death. The observation period extends up to November 2031 for malignancies and until November 2027 for infections. During the study, information about participants health will be collected from medical records over time. Researchers will monitor new cases of cancer, serious infections, and infection-related deaths. The study involves no treatment interventions beyond routine care and will last up to nearly six years, providing long-term safety data for patients with moderate to severe SLE.
CONDITIONS
Brief Title
Anifrolumab Malignancy and Serious Infections Study
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here